View Post

Lilly reports positive PRO from high-risk early breast cancer trial

In Clinical Studies News by Barbara Jacoby

From: clinicaltrialsarena.com Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC).  Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The move comes after a primary outcome analysis …

View Post

Lilly’s Verzenio scores a win in early-stage breast cancer

In Clinical Studies News by Barbara Jacoby

Positive data was presented at 2020 ESMO virtual congress In the monarchE trial, patients with hormone receptor positive (HR+), HER2-negative high-risk early breast cancer were given Verzenio (abemaciclib) in combination with endocrine therapy. In addition to cutting the risk of cancer recurrence by 25%, 7.8% of the Verzenio treatment group had a relapse compared to 11.3% of patient in the …

View Post

First New Drug in Years Reduces Recurrence in High-Risk Hormone Receptor Positive Early Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jill Murphy, Assistant Editor From: pharmacytimes.com Results from a study presented at the European Society of Modern Oncology 2020 found that adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer, according to a press release. The phase 3 …